TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26631095
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate 40 mg twice weekly with daily oral estrogen
Study: 26631095
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice weekly with daily oral estrogen
Study: 20886631
Drug: 5-fluorouracil or
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil or equivalent agents
Study: 19041049
Drug: Dofetilide (class
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dofetilide (class III antiarrhythmic drug)
Study: 16609032
Drug: l-selenomethionine (SeMet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-selenomethionine (SeMet)
Study: 11535875
Drug: Aspirin (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (160 or 300 mg/day)
Study: 3323604
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CyA) + Heparin
Study: 22796948
Drug: Bagel with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bagel with cream cheese and juice (400 kcal)
Study: 20399951
Drug: Advanced supply
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced supply of emergency contraception (EC) pills with unlimited supply thereafter upon request
Study: 8445015
Drug: Estradiol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (0.2 mg/day percutaneously)
Study: 8445015
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no estradiol treatment)
Study: 3518730
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg trimoprostil administered 30 min before meals
Study: 3518730
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg trimoprostil administered 30 min after meals
Study: 26432623
Drug: Basal-Bolus Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal-Bolus Insulin (B-BI)
Study: 26432623
Drug: Sliding Scale
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sliding Scale Insulin (SSI)
Study: 24338466
Drug: Intrathecal 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 7.5 mg Levobupivacaine 0.25% plus sufentanil 2.5 μg (Group L0.25)
Study: 24338466
Drug: Intrathecal 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 7.5 mg Levobupivacaine 0.50% plus sufentanil 2.5 μg (GroupControl)
Study: 21289522
Drug: AT-101 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT-101 (40 mg b.i.d. × 3 days) plus docetaxel (75 mg/m on day 1) every 21 days
Study: 21289522
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus docetaxel (75 mg/m on day 1) every 21 days
Study: 19649687
Drug: Morphine (MG)
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (MG)
Study: 19649687
Drug: Oxycodone (OG)
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone (OG)
Study: 21280077
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate 40 mg
Study: 21280077
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate 20 mg
Study: 15035723
Drug: Sodium antimony
Normalized name: Sodium antimonyl gluconate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium antimony gluconate (SAG) 20 mg/kg daily for 4 weeks
Study: 15035723
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (AMB) 1 mg/kg daily for 20 days
Study: 8154037
Drug: DILT (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: DILT (60 mg b.i.d.)
Study: 8154037
Drug: KETO (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: KETO (200 mg/day)
Study: 8154037
Drug: Control (TRIPLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (TRIPLE with CsA 8 mg/kg/day)
Study: 3292185
Drug: Amoxicillin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (3 g as a single dose)
Study: 3292185
Drug: Clindamycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (600 mg as a single dose)
Study: 3292185
Drug: Erythromycin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (1.5 g plus another 0.5 g after six hours)
Study: 28283600
Drug: Admission hyperglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Admission hyperglycemia (blood glucose ≥7.8 mmol/L)
Study: 26585940
Drug: Mammalian cell-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mammalian cell-derived quadrivalent influenza vaccine (QIVc)
Study: 26585940
Drug: Trivalent influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent influenza vaccines (TIV1c/TIV2c)
Study: 24251363
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing of warfarin (control)
Study: 21334545
Drug: Augmented soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented soft tissue mobilization (ASTM) twice a week for 5 weeks
Study: 8569932
Drug: Pyloriset IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyloriset IgG at a cut-off value of 500 U/l
Study: 8569932
Drug: Pyloriset IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyloriset IgG at a cut-off value of 350 U/l (excluding patients aged above 70 years)
Study: 2548135
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogens + 5 mg medroxyprogesterone acetate
Study: 2548135
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg conjugated equine estrogens + 5 mg medroxyprogesterone acetate
Study: 2548135
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogens + placebo
Study: 2548135
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg conjugated equine estrogens + placebo
Study: 18182665
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel plus prednisone (D1P)
Study: 15795146
Drug: PCEA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA plus continuous background infusion (4 mL/h plus an hourly maximum of three 4‐mL boluses on demand, lock‐out time 20 min)
Study: 15795146
Drug: Demand-only PCEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demand-only PCEA (hourly maximum of four 4‐mL boluses, lock‐out time 15 min)
Study: 15795146
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens (PCEA plus continuous background infusion and demand-only PCEA)
Study: 15795146
Drug: PCEA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA plus continuous background infusion
Study: 7006557
Drug: Imipramine hydrochloride
Normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imipramine hydrochloride (pharmacotherapy)
Study: 28301098
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg AER (under fasting conditions)
Study: 28301098
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg AER (under fed conditions)
Study: 28301098
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg CARP
Study: 28301098
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg AER
Study: 25400472
Drug: Perioperative restricted
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative restricted fluid therapy (R, n = 96)
Study: 25400472
Drug: Perioperative standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative standard fluid therapy (S, n = 89)
Study: 20482508
Drug: Buspirone (anxiolytic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (anxiolytic, 5-HT(1A) partial agonist)
Study: 20482508
Drug: Ritanserin (serotonergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin (serotonergic drug)
Study: 20482508
Drug: Ondansetron (5-HT(3)
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron (5-HT(3) antagonist)
Study: 20482508
Drug: SSRIs (Selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs (Selective serotonin reuptake inhibitors)
Study: 11879258
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg twice daily on days 2-6)
Study: 11879258
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg once daily on days 2-4)
Study: 10689656
Drug: Initial motivationally
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial motivationally based, four-session outpatient treatment; n = 67
Study: 2518847
Drug: Mesasal tablets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesasal tablets, 2 x 250 mg, fasting
Study: 2518847
Drug: Mesasal tablets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesasal tablets, 2 x 250 mg, fed
Study: 2518847
Drug: Salazopyrin tablets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salazopyrin tablets, 3 x 500 mg (corresponding to 576 mg 5‐ASA), fasting
Study: 2518847
Drug: Mesasal suppository,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesasal suppository, 1 x 500 mg, fasting
Study: 31495292
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg once then 850 mg twice daily for two weeks
Study: 31495292
Drug: Metformin (double
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (double dose 1700 mg)
Study: 31495292
Drug: Metformin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (single dose 850 mg)
Study: 15886247
Drug: Metformin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (both doses)
Study: 21291446
Drug: Mentoring (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentoring (treatment group)
Study: 17082240
Drug: ACEi (trandolapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEi (trandolapril 2 mg/d)
Study: 17082240
Drug: ndCCB (verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: ndCCB (verapamil SR 240 mg/d)
Study: 17082240
Drug: Veratran (trandolapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veratran (trandolapril 2 mg/d plus verapamil SR 180 mg/d)
Study: 11704899
Drug: Integrated Psychological
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Psychological Therapy Program (IPT)
Study: 7924757
Drug: Indomethacin (repeated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (repeated doses)
Study: 7924757
Drug: Indomethacin (third
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (third dose)
Study: 2891365
Drug: Neostigmine 2.5
Normalized name: neostigmine 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 2.5 mg
Study: 2891365
Drug: Neostigmine 5
Normalized name: neostigmine 5 mg/5 mL preservative-free intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 5 mg
Study: 18579227
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (aspirin plus clopidogrel)
Study: 29409488
Drug: Polydisperse pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polydisperse pMDI inhalation of salbutamol (400 μg)
Study: 20683947
Drug: High-dose ursodeoxycholic
Normalized name: ursodeoxycholate
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ursodeoxycholic acid (UDCA) 23-28 mg/kg/day
Study: 17630563
Drug: Protease inhibitor-based
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor-based antiretroviral therapy
Study: 17630563
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (general)
Study: 12697595
Drug: Ropivacaine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 15 mg plus morphine 150 micro g (RM group)
Study: 12697595
Drug: Bupivacaine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 15 mg plus morphine 150 micro g (BM group)
Study: 10823363
Drug: Hypericum (LI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum (LI 160) 600 mg/d for 1 week, then 900 mg/d for 6 weeks
Study: 10823363
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg/d for 1 week, then 75 mg/d for 6 weeks
Study: 9032863
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Gamma Knife treatment (surface dose 58 +/- 9 Gy, maximum dose 81 +/- 15 Gy, mean dose 66 +/- 11 Gy) in Group A (10 patients, follow-up 24 +/- 4 months)
Study: 9032863
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose Gamma Knife treatment (surface dose 41 +/- 3 Gy, maximum dose 76 +/- 10 Gy, mean dose 53 +/- 11 Gy) in Group B (9 patients, follow-up 16 +/- 2 months)
Study: 9032863
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose Gamma Knife treatment (surface dose 42 +/- 3 Gy, maximum dose 72 +/- 16 Gy, mean dose 54 +/- 6 Gy) in Group C (17 patients, follow-up 6 +/- 3 months)
Study: 1523880
Drug: Conjugate vaccine
Normalized name: meningococcal conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugate vaccine (11 micrograms of each oligosaccharide and 88 micrograms of CRM 197)
Study: 6389288
Drug: Quinine-papaverine combination
Normalized name: papaverine, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine-papaverine combination (3 X 1 coated tablet per day for four weeks)
Study: 30714482
Drug: Self-administered therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered therapy using a smart tablet (trained with functional words)
Study: 30714482
Drug: Self-administered therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered therapy using a smart tablet (trained with words from a picture database)
Study: 30714482
Drug: Self-administered therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered therapy using a smart tablet (exposed but not trained)
Study: 28102427
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg intravenous acetylsalicylic acid (ASA)
Study: 28102427
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg intravenous acetylsalicylic acid (ASA)
Study: 28102427
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral acetylsalicylic acid (ASA)
Study: 25692350
Drug: 4-dose Zagreb
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-dose Zagreb regimen
Study: 25692350
Drug: 5-dose Essen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-dose Essen regimen
Study: 23835708
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus pemetrexed 500 mg/m(2)
Study: 20042475
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate 50 mg kg(‐1) i.v. as a bolus and 15 mg kg(‐1) h(‐1) by continuous infusion during the operation
Study: 19032711
Drug: Multifamily group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifamily group therapy plus pharmacotherapy
Study: 19032711
Drug: Individual family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual family therapy plus pharmacotherapy
Study: 11799338
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg/day, increased to 100 mg after 4 weeks if inadequate response)
Study: 2779240
Drug: Alcohol (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.125 g/kg of 95% ethanol)
Study: 2779240
Drug: Alcohol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.25 g/kg of 95% ethanol)
Study: 2779240
Drug: Alcohol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.5 g/kg of 95% ethanol)
Study: 2779240
Drug: Concurrent schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent schedule of point presentation
Study: 2779240
Drug: Interaction between
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interaction between alcohol and concurrent point presentation contingencies
Study: 2779240
Drug: No alcohol
Normalized name: BENZALKONIUM CHLORIDE 0.13 g in 100 mL TOPICAL SOLUTION [Zoono Alcohol Free Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No alcohol (0 g/kg of 95% ethanol)
Study: 177873
Drug: Radiation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation with high-dose metronidazole
Study: 30032673
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg pyridoxine (placebo)
Study: 12799881
Drug: Medical and
Normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical and surgical treatment for GERD
Study: 7718367
Drug: i.m. ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. ketorolac 30 mg
Study: 7006657
Drug: morphine 10
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 10 mg
Study: 2074061
Drug: Psychological preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological preparation (cognitive-behavioral program, 'stress inoculation')
Study: 22104568
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) intervention
Study: 20032007
Drug: Fluconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (200 mg three times per week)
Study: 11837717
Drug: Alprostadil alfadex
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil alfadex at a dose of 0.05 microg/kg/min
Study: 11837717
Drug: Alprostadil alfadex
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil alfadex at a dose of 0.1 microg/kg/min
Study: 10368359
Drug: Ibuprofen (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1.2 g/day for 3 days)
Study: 29924642
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and Placebo
Study: 31606244
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (840 mg EPA and 560 mg DHA per day)
Study: 30206011
Drug: Traditional heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional heparin and protamine dosage based on body weight (Control group)
Study: 22156892
Drug: Buprenorphine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (20 μg/h)
Study: 22156892
Drug: Fentanyl (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (25 μg/h)
Study: 17343594
Drug: Collagen-polyvinylpyrrolidone (clg-pvp)
Normalized name: triacontanyl PVP (WP-660)
DrugBank: Collagen-polyvinylpyrrolidone (DB16525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen-polyvinylpyrrolidone (clg-pvp) applied at a rate of 1.5 ml intradermically at four equi-spaced points around the ulcer.
Study: 17343594
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution with polyvinylpyrrolidone) applied at a rate of 1.5 ml intradermically at four equi-spaced points around the ulcer.
Study: 28753384
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 (D75)
Study: 12108897
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m2 (D100)
Study: 3808504
Drug: strict management
Approvals — FDA: no, EMA: no, PMDA: no
Description: strict management (euglycemic: fasting blood glucose < 80 mg/dL, 1.5-hour postprandial blood glucose < 120 mg/dL)
Study: 3808504
Drug: customary management
Approvals — FDA: no, EMA: no, PMDA: no
Description: customary management (fasting blood glucose ≤ 100 mg/dL, postprandial blood glucose < 140 mg/dL)
Study: 21504883
Drug: Contact Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contact Control (CC)
Study: 17700438
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy added to general practitioners' care
Study: 8942589
Drug: IV droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV droperidol 1.25 mg and ondansetron 4 mg
Study: 8942589
Drug: IV droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV droperidol 1.25 mg and saline
Study: 2039720
Drug: Oral 8‐methoxypsoralen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 8‐methoxypsoralen photochemotherapy (PUVA) using ultraviolet fluorescent lamps with peak emission at 325 nm
Study: 2039720
Drug: Oral 8‐methoxypsoralen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 8‐methoxypsoralen photochemotherapy (PUVA) using ultraviolet fluorescent lamps with peak emission at 352 nm
Study: 2039720
Drug: Oral 8‐methoxypsoralen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 8‐methoxypsoralen photochemotherapy (PUVA) using ultraviolet fluorescent lamps with peak emission at 370 nm
Study: 7129805
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg nomifensine intravenously
Study: 7129805
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg nomifensine orally
Study: 7129805
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg nomifensine orally
Study: 31520608
Drug: Hygroscopic dilators
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hygroscopic dilators with misoprostol 400 mcg
Study: 31520608
Drug: No hygroscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No hygroscopic dilators with misoprostol 400 mcg
Study: 26553689
Drug: PsA‐TT (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PsA‐TT (2 doses)